Akums Drugs FY26 results: ₹3 dividend, revenue up

FY26 results put focus on growth and payouts

Akums Drugs and Pharmaceuticals has announced its financial results for the quarter and year ended March 31, 2026, alongside a dividend recommendation and key corporate dates. The Board of Directors has recommended a total dividend of ₹3.00 per share for the financial year, split between a final dividend of ₹1.00 per share and a special dividend of ₹2.00 per share. The company has also set the date for its Annual General Meeting (AGM) and disclosed the record date for dividend eligibility. Along with these shareholder-focused announcements, Akums indicated a positive outlook even as tax proceedings remain ongoing.

Consolidated FY26 performance versus last year

For the fiscal year ended March 31, 2026, Akums reported consolidated revenue from operations of ₹43,590.17 million. This compared with ₹41,181.58 million in the previous year, indicating higher revenue on a year-on-year basis. Consolidated net profit for the year stood at ₹2,563.97 million. These annual numbers were presented as part of the company’s year-end disclosure and form the base for the Board’s dividend recommendation.

Standalone FY26 numbers also disclosed

Alongside the consolidated figures, the company disclosed standalone performance for the year ended March 31, 2026. Standalone annual revenue was reported at ₹13,487.36 million. Standalone net profit for the year was ₹1,116.40 million. The disclosure separates consolidated and standalone performance, which can matter for investors tracking earnings quality and where profits are being generated.

Dividend proposal: ₹1 final plus ₹2 special

The Board has recommended a final dividend of ₹1.00 per share and a special dividend of ₹2.00 per share for FY26, taking the total recommended dividend to ₹3.00 per share. The company has fixed July 3, 2026 as the record date for determining shareholder eligibility for the dividend payment. The dividend remains subject to shareholder approval at the company’s 22nd AGM.

AGM date and other corporate actions

Akums has scheduled its AGM for July 10, 2026. In the same set of updates, the company announced key senior management changes, without detailing names or specific roles in the provided information. It also stated that it is maintaining a positive outlook despite ongoing tax proceedings, signalling that the matter remains active but not altering the company’s stated stance.

Q3FY26 call and operating metrics highlighted earlier

Separate from the year-end announcement, Akums had also discussed performance trends in its Q3FY26 earnings conference call updates. The company reported consolidated operating revenue of ₹11,600 million for Q3FY26, with growth of 14.8% year-on-year and 14% quarter-on-quarter. Operating EBITDA was reported at ₹1,470 million, up 21% year-on-year and 55.4% quarter-on-quarter. The EBITDA margin for the quarter was stated at 12.7%, indicating improvement during that period.

Segment signals: API and trade generics remained weak

The API business continued to face challenges in Q3FY26, with revenue of ₹540 million and negative EBITDA of ₹70 million. The company noted that the API loss narrowed from negative EBITDA of ₹110 million in Q3FY25. Trade generics revenue declined 18% year-on-year to ₹250 million, with an EBITDA loss of ₹30 million. These numbers underline that while consolidated performance improved in Q3FY26, certain segments remained under pressure.

Other reported quarterly datapoints and stock move

Reported quarterly data points in the provided information include sales of ₹10,175.30 million and net profit of ₹407.80 million for the quarter ended September 2025, versus sales of ₹10,330.90 million and net profit of ₹652.10 million for the quarter ended September 2024. Another reported set of quarterly metrics cites revenue of ₹10,240.30 million, a 2.99% QoQ decrease from ₹10,555.50 million, alongside operating profit of ₹498.70 million and net profit of ₹634.80 million.

On the market side, Akums Drugs & Pharmaceuticals’ share price was reported as rising 2.04% from a previous close of ₹443.15 to a last traded price of ₹452.15. The provided data also lists face value at ₹2.00 and dividend yield at 0.00%.

Key figures at a glance

Market impact: what investors will likely track next

For shareholders, the immediate markers are the record date of July 3, 2026 and the AGM date of July 10, 2026, where the dividend proposal is expected to be taken up for approval. The FY26 consolidated revenue comparison versus last year provides a measurable operating backdrop to the dividend decision. Investors may also track how the company manages the disclosed tax proceedings and whether there are further updates through formal filings.

Segment performance discussed earlier also frames expectations. The reported narrowing of losses in the API business and the continued EBITDA losses in trade generics are datapoints investors may weigh against the consolidated profitability and the company’s stated outlook.

Analysis: dividend plus disclosures signal a shareholder-heavy quarter

The combination of a special dividend and a final dividend makes the FY26 payout headline-driven, but the financial context remains important. The company has disclosed both consolidated and standalone profitability for FY26, allowing investors to compare earnings strength across reporting scopes. Separately, the Q3FY26 operating metrics show that Akums had also reported a period of stronger operating leverage and margin improvement, even as two businesses remained loss-making.

With multiple disclosures spanning FY26 results, corporate actions, and earlier quarterly operating metrics, the next confirmed checkpoint is shareholder approval at the AGM. Any further clarity on senior management changes and the status of tax proceedings is likely to remain filing-led.

Conclusion

Akums Drugs’ FY26 update combines higher consolidated revenue versus the prior year with a recommended ₹3.00 per share dividend and fixed corporate dates in July 2026. The dividend is subject to approval at the 22nd AGM on July 10, 2026, with the record date set for July 3, 2026. Investors will watch for AGM outcomes, any subsequent disclosures on senior management changes, and updates related to the ongoing tax proceedings.